Klotho Neurosciences Moves Forward with Manufacturing Gene Therapy for the Treatment of ALS
A unique RNA splice variant of the human gene called alpha-Klotho has been licensed by the Company from the Autonomous University of Barcelona ('UAB') including patents, patent applications, research, knowhow and other intellectual properties for use in the development of advanced gene and gene-engineered cell therapies. The human alpha-Klotho gene is located in cells found throughout the human body. It is a five exon gene that produces two protein isoforms: a full-length protein found mainly in cells of the kidney called membrane-bound Klotho (or m-KL), which controls phosphate homeostasis, and a much smaller protein isoform called secreted alpha-Klotho (or s-KL). The s-KL RNA splice variant is found mainly in the brain and spinal cord neurons; the variant protein is neuroprotective by minimizing both oxidative stress and neuroinflammation. Animal studies supported by the Company over the past two years in mouse and non-human primate models of rapid aging, in models of human Alzheimer's disease, and in models of ALS have shown that over-expression and amplification of the tissue levels of s-KL using a gene therapy approach result in highly favorable therapeutic outcomes in every model tested. These results have been published in peer-reviewed scientific journals and now support the transition of KLTO-202 into the clinical development stage.
The Company expects that it will take approximately eight months to complete process development and manufacturing of KLTO-202, and about four to six months to conduct meetings with FDA, complete all FDA-mandated animal safety studies, file an investigational new drug application (IND), train and prepare clinical sites where the Phase I/II studies can be conducted, and then begin the single-dose gene therapy studies in ALS patients by the third quarter of next year. The Company will work with contract research organizations (CROs) to facilitate all activities including manufacturing and clinical trials without the need to hire several dozen staff members, which would significantly increase our operating overhead.
Dr. Joseph Sinkule, the Company's CEO and founder commented: 'With our recent fundraising success, we're moving forward with manufacturing the s-KL transgene DNA for KLTO-202. We've identified a more efficient method of producing the AAV vector to deliver the s-KL gene directly to motor neurons—the cells most affected by ALS. Our goal is to increase local s-KL protein levels to protect these neurons from the damage that leads to voluntary and involuntary muscle paralysis and ultimately death.'
ALS typically progresses rapidly, with most patients losing mobility, respiratory function, and life within just 2–3 years of diagnosis.
About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the 'anti-aging' human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The Company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization.
Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO
[email protected]
Website: www.klothoneuro.com
Forward-Looking Statements:
This press release contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the 'SEC') from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
View original content to download multimedia: https://www.prnewswire.com/news-releases/klotho-neurosciences-moves-forward-with-manufacturing-gene-therapy-for-the-treatment-of-als-302494100.html
SOURCE Klotho Neurosciences, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Jackson Hole, key retail earnings, and fresh economic data: Here's everything the stock market is watching this week
Markets are kicking off another news- and data-heavy week. Investors are watching for the July Fed minutes, fresh housing data, and a slew of retail earnings. The spotlight will be on Fed Chair Jerome Powell's comments at Jackson Hole on Friday. Get ready for another big week for the stock market. Investors are staring at a handful of catalysts on the radar this week, with a slew of fresh earnings reports and key signals from the Fed on the docket. All could be influential in determining the path ahead for Fed rate cuts — a bullish catalyst investors have been waiting for all year. Odds for a cut next month have edged down slightly since last week, but markets are still pricing in an 85% chance the Fed will cut rates by a quarter of a percentage point at the September meeting, according to the CME FedWatch Tool. Here's what investors will be reacting to this week. Fed minutes Investors will be paying close attention to the minutes from the Fed's July policy meeting on Wednesday. The meeting minutes will give markets more insight into the central bank's thoughts about inflation, the strength of the US economy, and its outlook for rate cuts going forward. It comes at a crucial time for the Fed, which is at a crossroads over the direction of monetary policy. Powell has continued to signal this year that the Fed is comfortable keeping rates steady, as officials wait to see the inflationary impact of tariffs. But inflation data has been mixed recently. Consumer prices rose in-line with economists' expectations last month, but wholesale inflation rose more than expected in the latest producer price index, a sign that more inflationary pressures could be building. Meanwhile, the job market has shown signs of cooling. The US added fewer jobs than expected in July, while job gains in May and June were revised downward by a combined 258,000. "Traders will be closely watching the minutes for more insight into the future rate-cut trajectory," Aaron Hill, an analyst at FP Markets, wrote in a note. "Still, the slowdown in the labour market data, as noted above, firmly swung the pendulum in favour of easing policy next month." "At the margin, the minutes of the July 29-30 FOMC meeting (Wed) could fill in some blanks about how dug in the doves were and how intransigent the inflation hawks might've been in late July," Ed Yardeni, the president of Yardeni Research, wrote over the weekend. Retail earnings Investors are also waiting on a slew of earnings reports from major retailers this week. Here are the companies on deck to report their second-quarter results: Tuesday Wednesday Thursday Friday Home Depot (HD) TJX Companies (TJX) Lowe's (LOW) Target (TGT) Walmart (WMT) BJ Wholesale Club (BJ) The coming reports will give investors a glimpse into how the US consumer is faring. Weak earnings are likely to fan concerns about economic growth and raise expectations for a Fed rate cut next month. Markets are looking at the coming earnings reports as "key signposts" this week, top economist David Rosenberg said. "In terms of the mood of the US consumer, it is none too good (and as we saw in Friday's retail sale report, there is a trend in place towards dining in over dining out which is a sure sign of consumer frugality," the Rosenberg Research founder wrote in a note. Jackson Hole All eyes will be on Fed Chair Jerome Powell on Friday. The central bank chief is set to speak at the Fed's annual Jackson Hole symposium, where he's expected to set the agenda for future rate cuts. Markets are also eager to see if the Fed Chair comments on the independence of the central bank. President Donald Trump has continued to pressure Powell to lower interest rates, and is narrowing his list of potential Fed candidates. The speech could "well be a market-mover" this week, Rosenberg added. "One hawkish surprise could come from any commentary about how the weakness in the labor market of late has come largely from the supply side, and the 'break-even' for job growth to keep the unemployment rate steady is far lower than it used to be," Rosenberg wrote. "We expect the Federal Reserve to use Jackson Hole as an opportunity to prepare the markets and signal towards a 25 basis point cut in September and a potentially accommodating stance through year-end. Since this will be Powell's last Jackson Hole conference as Fed Chair, he'll likely reinforce the need for Fed independence from the Executive Branch," Richard Saperstein, the chief investment office of Treasury Partners, wrote in a note. Stocks could see some selling pressure once Powell speaks on Friday, strategists at Bank of America wrote in a note last week. "Dovish Powell at Jackson Hole = buy rumor, sell fact profit-taking," a team led by Michael Hartnett said. Read the original article on Business Insider
Yahoo
5 minutes ago
- Yahoo
Bausch + Lomb board members resign after Icahn agreement ends
(Reuters) -Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates. The agreement, dated June 21, 2022, ended after the Icahn group's net long position in Bausch Health Companies, Bausch + Lomb's parent, fell below the required threshold. On Friday, Bausch Health said Paulson Capital, along with certain affiliates and managed funds, increased their position in the company and acquired about 34.7 million common shares previously held by the Icahn Group. In April, Carl Icahn had built an economic interest covering about 34% of Bausch Health's shares. Sign in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Vulcan Elements signs rare earths supply deal with ReElement Technologies
(Reuters) -Vulcan Elements, a North Carolina-based rare earth magnet manufacturer, has agreed to buy a supply of the critical minerals from ReElement Technologies that will be sourced outside of China. The companies, both of which are privately held, declined to give precise financial terms but said that the price is "significantly below" the floor of $110 per kilogram that the U.S. Department of Defense guaranteed to MP Materials last month for the two most popular rare earths. The contract was signed in mid-July, Vulcan said. Rare earth oxides are used to make metal that can then be turned into magnets for use in fighter jets, radar and other military applications, as well as consumer electronics. "This pricing will enable Vulcan to be competitive in global markets," Vulcan CEO John Maslin told Reuters. "We wanted to make sure the unit economics made sense." Indiana-based ReElement, which licenses its technology from Purdue University, will supply Vulcan with "thousands of metric tons" of rare earth oxides annually for five years beginning in 2026 from outdated electronics or from mine sites, said CEO Mark Jensen. ReElement says it can supply the rare earths to Vulcan below $110 per kilogram because of its use of a processing technique known as chromatography, which is different than the industry-standard solvent extraction used by many of its peers. "We are laser focused on cost," Jensen told Reuters. "We will see where the market goes, but right now we're focused more on the market price versus that price floor." Reuters was first to report last month that the Trump administration is considering extending that price floor to other firms, news that was relayed in a close-door Washington meeting attended by Vulcan, ReElement and others.
